http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TR-201819940-T4

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d0898273b063708ec261866b5889712
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-438
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
filingDate 2009-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b5cfe716582c91fdd110c6222e02c21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a95899e3729c246ca4795a070f34b3c6
publicationDate 2019-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber TR-201819940-T4
titleOfInvention Methods and compositions for treating inflammatory bowel disease.
abstract The present disclosure provides improved compositions containing rifabutin, clarithromycin and clofazimine for the treatment of Inflammatory Bowel Diseases. In one example, these compositions are capsules, tablets, etc. with one or more specific additives. may contain a formulation of rifabutin, clarithromycin and clofazimine in single dose form such as.
priorityDate 2008-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407386600
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID84029
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457619940
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398743
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2794
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503223

Total number of triples: 37.